Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer

Inclusion Criteria: * Signed written informed consent prior to beginning protocol specific procedures * Male or female \> 18 years of age * Histologically proven diagnosis of adenocarcinoma of the stomach * HER2 negative tumor or HER2+ tumors not qualifying for herceptin therapy * Locally advanced (non resectable) or metastatic gastric cancer * Presence of measurable disease with at least one measurable lesion by means of CT scan or MRI in not previously irradiated area(s) (according to RECIST criteria (version 1.1) * Life expectancy of \>/= 3 months * ECOG performance status of 0-2 at study entry * Neutrophils \>/= 2.0 x 1000000000/L, platelets \>/= 100 x 1000000000/L, and hemoglobin \>/= 10 g/dL * Bilirubin level either normal or \</= 1.5 x ULN * AST and ALT \</= 2.5 X UNL (\</= 5 x ULN if liver metastasis are present * Alkaline phosphatase (ALP) \</= 2.5 X ULN; patients with alkaline phosphatase \> 2.5x ULN and AST and ALT \</= 1.5 x ULN are equally eligible * Serum creatinine \< 1.5 x ULN. In presence border-line values, the calculated creatinine clearance should be \>/= 60 mL/min * Negative pregnancy test (if female in reproductive years) * Effective contraception prior to study entry and for the duration of the study participation, for both male and female patients of child producing potential * Able and willing to comply with scheduled visits, therapy plans and laboratory tests required in this protocol Exclusion Criteria: * Previous chemotherapy, except adjuvant treatment administered at least 1 year before study entry * Concurrent chronic systemic immune therapy * Any investigational agent(s) 4 weeks prior to entry * Clinically relevant coronary artery disease or a history of a myocardial infarction or a history of hypertension not controlled by therapy within the last 12 months * Known hypersensitivity to study drugs. Known grade 3 or 4 allergic reaction to any of the components of the treatment * Known drug abuse/ alcohol abuse * Acute or subacute intestinal occlusion and any other significant chronic gastrointestinal disease that might interfere with absorption of oral treatment * History of clinically relevant psychiatric disability precluding informed consent * Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * Pregnant or breastfeeding women * Active uncontrolled infection(s) * Positive for HIV serology and/or viral hepatitis B or C * Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix. (Patients with a previous malignancy but without evidence of disease for ≥ 5 years will be allowed to enter the trial)